Véronique
Véronique Arnoult Delest, Antony FR
Patent application number | Description | Published |
---|---|---|
20120251664 | FRESH DAIRY PRODUCTS WITH SATIETOGENIC POWER AND METHODS FOR PREPARING SAME - The invention concerns a fresh dairy product with low fat and sugar content and low energy density, comprising one or several satietogenic ingredients, as well as a method for making such a product. Said satietogenic ingredient(s) comprise proteins, in particular milk proteins and preferably serum milk proteins, associated with water-soluble dietary fibers and preferably viscosifying water-soluble dietary fibers. | 10-04-2012 |
Véronique Barban, Craponne FR
Patent application number | Description | Published |
---|---|---|
20100137571 | DENGUE SEROTYPE 1 ATTENUATED STRAIN - The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain. | 06-03-2010 |
20100174057 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 07-08-2010 |
20100221285 | Method of Immunization Against the 4 Dengue Serotypes - The invention relates to a method for inducing a homologous protection against the 4 dengue serotypes in a patient, comprising the sequential administration, to said patient, (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, in which the vaccinal dengue viruses (ii) are administered at least 30 days and at most 1 year after administration of the vaccinal viruses (i). | 09-02-2010 |
20100239612 | Method of Immunization Against the 4 Serotypes of Dengue Fever - The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising: | 09-23-2010 |
20100270202 | Method of Immunization Against the 4 Dengue Serotypes - The invention relates to a method for inducing a protection against the 4 dengue serotypes in a patient, comprising | 10-28-2010 |
20150031857 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 01-29-2015 |
Véronique Barban, Craponne FR
Patent application number | Description | Published |
---|---|---|
20100137571 | DENGUE SEROTYPE 1 ATTENUATED STRAIN - The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain. | 06-03-2010 |
20100174057 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 07-08-2010 |
20100221285 | Method of Immunization Against the 4 Dengue Serotypes - The invention relates to a method for inducing a homologous protection against the 4 dengue serotypes in a patient, comprising the sequential administration, to said patient, (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, in which the vaccinal dengue viruses (ii) are administered at least 30 days and at most 1 year after administration of the vaccinal viruses (i). | 09-02-2010 |
20100270202 | Method of Immunization Against the 4 Dengue Serotypes - The invention relates to a method for inducing a protection against the 4 dengue serotypes in a patient, comprising | 10-28-2010 |
20120083584 | DENGUE SEROTYPE 1 ATTENUATED STRAIN - The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain. | 04-05-2012 |
20120083585 | DENGUE SEROTYPE 2 ATTENUATED STRAIN - The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain. | 04-05-2012 |
Véronique Bellon Maurel, Grabels FR
Patent application number | Description | Published |
---|---|---|
20120229809 | SELF-CONTAINED AND PORTABLE OPTICAL SPECTROMETER - The invention relates to a portable and self-contained optical spectrometer for analyzing a light spectrum backscattered by an illuminated sample, in order to deduce the content of at least one compound constituting the sample, said spectrometer being arranged about an optical axis and including: a target area centered on said optical axis; a plurality of optical sensors trained on the target area; an opaque measurement chamber including: an opening centered on said optical axis; at least one diffusing filter blocking said opening; and an inner bottom capable of housing the plurality of optical sensors and a main illumination device capable of illuminating the sample. The invention further relates to a method for using such a spectrometer. | 09-13-2012 |
Véronique Bonnelye, Conflans Sainte Honorine FR
Patent application number | Description | Published |
---|---|---|
20110290723 | METHOD AND PLANT FOR MANAGING THE CLOGGING OF MEMBRANE MODULES AND FILTRATION MEMBRANES - The invention relates to a method for managing the plugging of membrane modules and of filtration membranes, in particular for nanofiltration, ultrafiltration or reverse osmosis for desalinating water, which comprises carrying out consecutive rinsing operations for controlling clogging, in particular biological clogging: evaluating the thickness of the biofilm; starting a rinsing operation at the latest when the evaluated thickness of the biofilm exceeds a first predetermined setpoint value for the biofilm thickness and stopping the rinsing operation not before the biofilm thickness has become lower than a second predetermined setpoint value lower than the first one for the biofilm thickness. | 12-01-2011 |
Véronique Bonnelye, Conflans FR
Patent application number | Description | Published |
---|---|---|
20110147285 | REVERSE-OSMOSIS WATER DESALINATION PLANT - The invention relates to a reverse-osmosis water desalination plant comprising: a reverse-osmosis membrane unit (TP); at least one high-pressure pump (HP); a pressure-exchange-type energy collector (SRE) capable of transferring pressure from the concentrate leaving the membrane unit to a portion of the water to be treated; sensors for various operating parameters, in particular pressure, flow rate, temperature and salinity level, said sensors being provided at suitable locations; and control loops so that the various adjustable elements are maintained at a setpoint value. The plant also includes a secondary control system (D) comprising calculation means ( | 06-23-2011 |
Véronique Bonnelye, F-Conflans Sainte Honorine FR
Patent application number | Description | Published |
---|---|---|
20110186512 | PROCESS FOR DISINFECTING A FILTRATION WORKS FOR PRETREATMENT OF SALTWATER, AND INSTALLATION FOR THE IMPLEMENTATION THEREOF - Method for disinfecting a filtration works (F) for the pretreatment of salt water, particularly seawater, upstream of a water desalination unit ( | 08-04-2011 |
Véronique Bordas, Antony FR
Patent application number | Description | Published |
---|---|---|
20110293665 | Recombinant Der P 2 Expressed in Pichia Pastoris as a "Natural-Like" Allergen for Immunotherapy and Diagnostic Purposes - The present invention concerns a method for producing a recombinant | 12-01-2011 |
Véronique Bossennec, Serezin Du Rhone FR
Patent application number | Description | Published |
---|---|---|
20100152324 | COMPOSITION STABILIZED WITH RESPECT TO LIGHT AND/OR HEAT - The present invention relates to a polyamide-based composition stabilized with respect to light and/or heat comprising at least one stabilizer exhibiting at least one hindered amine functional group. The invention also relates to yarns, fibres, filaments and/or articles obtained from this composition. | 06-17-2010 |
20120046439 | PROCESS FOR THE MANUFACTURE OF A SOLUTION OF SALTS OF DIACIDS/DIAMINE(S) - A method for manufacturing a solution of a diacid and diamine salt for manufacturing polyamide is described. A method for manufacturing an aqueous solution of diacid and diamine salts produced by mixing at least two diacids and at least one diamine, with a weight concentration of salt between 40% and 70%, including, in a first step, preparing an aqueous solution of diacid(s) and diamine(s) with a diacid/diamine mole ratio of less than 1 using one diacid and one diamine, and in a second step, adjusting the mole ratio of diacids/diamine(s) to a value of between 0.9 and 1.1, and fixing the weight concentration of salt by adding another diacid and, optionally, additional water and/or diamine is also described. | 02-23-2012 |
Véronique Bossennec, Serezin Du Rhone FR
Patent application number | Description | Published |
---|---|---|
20090246448 | THERMOPLASTIC POLYMER/COLORANT TOW AND FLOCKED ARTICLES PREPARED THEREFROM - A continuous filament thermoplastic polymer/colorant tow, the filaments of which are formed from a composition containing at least one matrix including a thermoplastic polymer and a colorant, and, optionally, at least one light and/or heat stabilizer, and is converted into useful flocked articles, e.g., vehicle interiors, having such properties as good light and/or heat fastness. | 10-01-2009 |
20100152324 | COMPOSITION STABILIZED WITH RESPECT TO LIGHT AND/OR HEAT - The present invention relates to a polyamide-based composition stabilized with respect to light and/or heat comprising at least one stabilizer exhibiting at least one hindered amine functional group. The invention also relates to yarns, fibres, filaments and/or articles obtained from this composition. | 06-17-2010 |
Véronique Carron, Claix FR
Patent application number | Description | Published |
---|---|---|
20100117238 | METHOD FOR PREPARING A LAYER COMPRISING NICKEL MONOSILICIDE NISI ON A SUBSTRATE COMPRISING SILICON - The invention relates to a method for fabricating a layer comprising nickel monosilicide NiSi on a substrate comprising silicon successively comprising the following steps: | 05-13-2010 |
Véronique Carron, Claix FR
Patent application number | Description | Published |
---|---|---|
20100117238 | METHOD FOR PREPARING A LAYER COMPRISING NICKEL MONOSILICIDE NISI ON A SUBSTRATE COMPRISING SILICON - The invention relates to a method for fabricating a layer comprising nickel monosilicide NiSi on a substrate comprising silicon successively comprising the following steps: | 05-13-2010 |
20110143534 | METHOD FOR FORMING METALLIC MATERIALS COMPRISING SEMI-CONDUCTORS - The method for forming first and second metal-based materials comprises providing a substrate comprising an area made from a first semi-conductor material and an area made from a second semi-conductor material comprising germanium separated by a pattern made from dielectric material, depositing a metal layer and performing a first heat treatment in an atmosphere comprising a quantity of oxygen comprised between 0.01% and 5%. The metal layer reacts with the first semi-conductor material and the second semi-conductor material comprising germanium to respectively form the first metal-based material and the second metal-based material containing germanium. | 06-16-2011 |
Véronique Charpeignet, Toulon FR
Patent application number | Description | Published |
---|---|---|
20120110265 | SECURISATION OF A REMOTE EXECUTABLE CODE USING A FOOTPRINT OF THE COMPUTER RECIPIENT - Method of securing exchanges between two electronic devices, by using an imprint of at least one of the two devices. This imprint is obtained on the basis of all or part of the electronic components of which this device is composed. This imprint will serve, either to protect the confidentiality of the data exchanged, or to attest to the identity of the device issuing the data. | 05-03-2012 |
Véronique Delcenserie, Ontario BE
Patent application number | Description | Published |
---|---|---|
20100310513 | BIFIDOBACTERIAL SPECIES - New bacterium GC61 belonging to the genus | 12-09-2010 |
Véronique Delcenserie, Ontario BE
Patent application number | Description | Published |
---|---|---|
20100310513 | BIFIDOBACTERIAL SPECIES - New bacterium GC61 belonging to the genus | 12-09-2010 |
Véronique Dennin, Villeneuve D'Ascq FR
Patent application number | Description | Published |
---|---|---|
20100322964 | BACTERIAL COMPOSITION AND ITS USE - The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of | 12-23-2010 |
20120135036 | BACTERIAL COMPOSITION AND ITS USE - The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of | 05-31-2012 |
Véronique Dennin, Villeneuve D'Ascq FR
Patent application number | Description | Published |
---|---|---|
20100322964 | BACTERIAL COMPOSITION AND ITS USE - The subject of the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of | 12-23-2010 |
Véronique Dentan, Paris FR
Patent application number | Description | Published |
---|---|---|
20120035484 | USE OF A SYSTEM FOR IMAGING BY FIBER-OPTIC CONFOCAL FLUORESCENCE IN VIVO IN SITU, SYSTEM AND METHOD FOR IMAGING BY FIBER-OPTIC CONFOCAL FLUORESCENCE IN VIVO IN SITU - A method for imaging a tissue includes collecting a light signal from at least part of said tissue, using a fiber optic probe for fluorescence imaging, wherein the fiber optic probe comprises a plurality of optic fibers, and wherein a distal tip of the fiber optic probe is placed at a distance from said tissue, said imaging being made confocal at a proximal tip of said fiber optic probe. A fluorescence imaging system includes an endoscope equipped with a working channel, in which a fiber optic probe has been inserted, wherein the fiber optic probe is movable between a retracted position and at least one position of extension, said fiber optic probe comprising a plurality of optic fibers for performing imaging of a tissue, said imaging being confocal via a processor located at a proximal tip of said fiber optic probe. | 02-09-2012 |
Véronique Dewynter-Marty, Gif S/yvette FR
Patent application number | Description | Published |
---|---|---|
20100290062 | Microstructured fibre bragg grating sensor - The invention involves a sensor ( | 11-18-2010 |
Véronique Dewynter-Marty, Gif S/yvette FR
Patent application number | Description | Published |
---|---|---|
20100290062 | Microstructured fibre bragg grating sensor - The invention involves a sensor ( | 11-18-2010 |
Véronique Ducandas, Vitry Sur Seine FR
Patent application number | Description | Published |
---|---|---|
20110152311 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT - The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described. | 06-23-2011 |
Véronique Durieu, Sombreffe BE
Patent application number | Description | Published |
---|---|---|
20100292188 | Compounds Comprising A Cyclobutoxy Group - The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals. | 11-18-2010 |
Véronique Durieu, Sombreffe BE
Patent application number | Description | Published |
---|---|---|
20100292188 | Compounds Comprising A Cyclobutoxy Group - The present invention relates to compounds of formula (I) comprising a cyclobutoxy group, processes for preparing them, pharmaceutical compositions comprising said compounds and their use as pharmaceuticals. | 11-18-2010 |
Véronique Gelsi-Boyer, Marseille FR
Patent application number | Description | Published |
---|---|---|
20130059301 | ASXL1 AS A NEW DIAGNOSTIC MARKER OF MYELOID NEOPLASMS - A method for diagnosing a myeloid cancer in a subject, includes the step of analyzing a biological sample from the subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID N°2. A kit for diagnosing myeloid cancer in a subject including at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method is also described. | 03-07-2013 |
Véronique Gomord, Rouen FR
Patent application number | Description | Published |
---|---|---|
20090312240 | Synthesis of Sialic Acid in Plants - A method of synthesizing sialic acid in plants, and plants capable of synthesizing sialic acid is provided. Furthermore, a method of producing sialylated a protein in a plant is also provided. The method to synthesize sialic acid comprises providing a plant comprising a nucleotide sequence encoding N-acetyl neuraminic acid (Neu5Ac) synthase or Neu5Ac lyase, and expressing the nucleotide sequence thereby synthesizing sialic acid. The plant may also co-express a nucleotide sequence encoding one or more than one of an epimerase, a CMP-Neu5 Ac synthase, CMP-Neu5Ac transporter and a sialyltransferase. | 12-17-2009 |
20110195452 | SET OF SEQUENCES FOR TARGETING EXPRESSION AND CONTROL OF THE POST-TRANSLATIONAL MODIFICATION OF A RECOMBINANT POLYPEPTIDE - The present invention provides new tools useful for controlling the post-translational modifications of recombinant polypeptides. These tools are particular signal peptides allowing the targeting of recombinant polypeptides during their synthesis in a host cell to specific sub-cellular compartments and a specific designing of said recombinant polypeptides within said sub-cellular compartments. These signal peptides are SEQ ID no 1 to SEQ ID no 31 disclosed herein. The present invention relates therefore also to a process for producing a recombinant polypeptide, in particular to a post-translationally modified polypeptide comprising the steps of transfecting or transforming a cell with at least one numleic acid vector encoding a recombinant protein which is the polypeptide before being post-translationally modified or a recombinant protein different to said polypeptide, said recombinant protein comprising a peptide signal according to the present invention; growing the transfected cell; and harvesting the post-translationally modified polypeptide; wherein, when said recombinant protein is different to said polypeptide, the method also comprises a step of transfecting said cell with at least one vector encoding said polypeptide. The present invention allows advantageously, for example, to increase the yield of production of recombinant polypeptides, to prevent immunogenicity if recombinant polypeptides and to obtain therapeutically active recombinant polypeptides that are the exact copy of their natural counterpart. This invention relates particularly to the field of reorientation of plants made pharmaceuticals (PMP). | 08-11-2011 |
Véronique Grenier-Caussanel, Saint Martin Du Fresne FR
Patent application number | Description | Published |
---|---|---|
20110020218 | NOVEL ANTI CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. | 01-27-2011 |
20110287451 | NOVEL ANTI CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. | 11-24-2011 |
20130031647 | HUMANIZED ANTI CXCR4 ANTIBODIES FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated humanized antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to hz515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered. | 01-31-2013 |
20140050661 | NOVEL ANTI-CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. | 02-20-2014 |
Véronique Grenier-Caussanel, Saint Martin Du Fresne FR
Patent application number | Description | Published |
---|---|---|
20110020218 | NOVEL ANTI CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. | 01-27-2011 |
20110294156 | NOVEL ANTI CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. | 12-01-2011 |
20130031647 | HUMANIZED ANTI CXCR4 ANTIBODIES FOR THE TREATMENT OF CANCER - The present invention relates to a novel isolated humanized antibody, or the derived compounds or functional fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and/or heterodimers. More particularly, the present invention relates to hz515H7 antibodies, specific to the CXCR4 protein, as well as their use for the treatment of cancer. Pharmaceutical compositions composed of such antibodies and a process for the selection of such antibodies are also covered. | 01-31-2013 |
Véronique Guyot-Ferreol, Paris FR
Patent application number | Description | Published |
---|---|---|
20090104135 | Use of Mineral/Organic Composite Material in the Form of an Ultraviolet Radiation Protective Agent - The invention relates to the use of composite material which comprises nanoparticles of a least one metal derivative and at least one organic sunscreen agent which is chemically bound with said particles in a covalent manner in the form of an ultraviolet radiation protective agent containing the inventive composite material. Cosmetic ultraviolet radiation protective compositions comprises said mixture are also disclosed. | 04-23-2009 |
20100291166 | USE OF NITROGEN-DOPED TITANIUM OXIDE NANOPARTICLES AS AGENTS FOR PROTECTING AGAINST ULTRAVIOLET RADIATION - A nanometric material includes nitrogen-doped titanium oxides, which is obtained by injection of a titanium oxide precursor in the liquid or gaseous form and of a gaseous nitrogenous compound into a laser pyrolysis reactor. The material is used as cosmetic agent for protecting against ultraviolet radiation, thereby improving protection against UV radiation and in particular against UV-A radiation. | 11-18-2010 |
Véronique Guyot-Ferreol, Paris FR
Patent application number | Description | Published |
---|---|---|
20100291166 | USE OF NITROGEN-DOPED TITANIUM OXIDE NANOPARTICLES AS AGENTS FOR PROTECTING AGAINST ULTRAVIOLET RADIATION - A nanometric material includes nitrogen-doped titanium oxides, which is obtained by injection of a titanium oxide precursor in the liquid or gaseous form and of a gaseous nitrogenous compound into a laser pyrolysis reactor. The material is used as cosmetic agent for protecting against ultraviolet radiation, thereby improving protection against UV radiation and in particular against UV-A radiation. | 11-18-2010 |
Véronique Hall-Goulle, Dornach CH
Patent application number | Description | Published |
---|---|---|
20080206658 | Compositions Containing Anthraquinone Dyes - A composition composition containing (A) an alkali-soluble binder and (B) an anthraquinone dye of formula (I) wherein R | 08-28-2008 |
20100021831 | TRANSPARENT COLOURANTS AND COLOURANT COMPOSITIONS, AND THEIR USE - The invention relates to a colourant composition comprising in a weight ratio of from 99:1 to 10:90, preferably a weight ratio of from 95:5 to 30:70, particularly preferred a weight ratio of from 95:5 to 50:50, a pigment of average particle size from 10 to 200 nm and a 1- or 2-phenylthio-substituted anthraquinones of greenish-yellow colour hue, lacking electron-rich N | 01-28-2010 |
20100186891 | NIR-INERT SUBSTRATES COMPRISING BIS-OXODIHYDROINDOLYLEN-BENZODIFURANONES - A method for producing infra-red inert substrates, including moulded polymeric articles, films, fibers and coatings and other organic and inorganic materials, by incorporating into the substrate or onto the surface of the substrate an effective amount of a dispersed bis-oxodihydroindolylen-benzodifuranone colourant. The thus obtained, also claimed substrates so produced are reflective and transparent to much of the near infra red radiation not reflected. There are multiple applications for cases of devices comprising electronic components, outdoor construction elements, outdoor furniture, automotive, marine or aerospace parts, laminates, artificial leather or textile materials, as well as in polychrome printing processes and optical fibers. The thus obtained substrates can also be subjected to laser welding. New bis-oxo-dihydroindolylen-benzodifuranone compounds are also claimed. | 07-29-2010 |
20100227199 | Blue Colour Filters with Enhanced Contrast - The invention relates to a process for enhancing the contrast of colour filters comprising α copper phthalocyanine or ε copper phthalocyanine, wherein a 1,4-diamino-anthraquinone dye or 1,9-annellated derivative thereof, of which the most bathochromic solution absorption peak in the visible spectrum is at from 575 to 615 nm, preferably at from 585 to 605 nm (as compared with around 630 nm for usual 1,4-diamino-anthraquinone dyes or 1,9-annellated derivatives thereof) is used in combination with α copper phthalocyanine or ε copper phthalocyanine. Also claimed are colour filters comprising such 1,4-diamino-anthraquinone dyes or 1,9-annellated derivatives thereof, as well as a novel compound of Formula (II), wherein R | 09-09-2010 |
20110112234 | PIGMENT MIXTURES - The present invention relates to novel pigment mixtures, comprising two different components A and B, wherein component A is a graphite in the form of platelets (graphite nanoplatelets), which have an average particle size of below 50 microns and a thickness below 100 nm, and component B is an organic, or inorganic pigment. The use of graphite nanoplatelets in a pigment mixture with organic and/or inorganic pigments, especially effect pigments (component B), allows the preparation of metallic like colorations with a maximal opacity (background substrate disappears totally) while keeping a good rheological behavior (low concentration use). | 05-12-2011 |
Véronique Hall-Goulle, Dornach CH
Patent application number | Description | Published |
---|---|---|
20100021831 | TRANSPARENT COLOURANTS AND COLOURANT COMPOSITIONS, AND THEIR USE - The invention relates to a colourant composition comprising in a weight ratio of from 99:1 to 10:90, preferably a weight ratio of from 95:5 to 30:70, particularly preferred a weight ratio of from 95:5 to 50:50, a pigment of average particle size from 10 to 200 nm and a 1- or 2-phenylthio-substituted anthraquinones of greenish-yellow colour hue, lacking electron-rich N | 01-28-2010 |
20100186891 | NIR-INERT SUBSTRATES COMPRISING BIS-OXODIHYDROINDOLYLEN-BENZODIFURANONES - A method for producing infra-red inert substrates, including moulded polymeric articles, films, fibers and coatings and other organic and inorganic materials, by incorporating into the substrate or onto the surface of the substrate an effective amount of a dispersed bis-oxodihydroindolylen-benzodifuranone colourant. The thus obtained, also claimed substrates so produced are reflective and transparent to much of the near infra red radiation not reflected. There are multiple applications for cases of devices comprising electronic components, outdoor construction elements, outdoor furniture, automotive, marine or aerospace parts, laminates, artificial leather or textile materials, as well as in polychrome printing processes and optical fibers. The thus obtained substrates can also be subjected to laser welding. New bis-oxo-dihydroindolylen-benzodifuranone compounds are also claimed. | 07-29-2010 |
20100227199 | Blue Colour Filters with Enhanced Contrast - The invention relates to a process for enhancing the contrast of colour filters comprising α copper phthalocyanine or ε copper phthalocyanine, wherein a 1,4-diamino-anthraquinone dye or 1,9-annellated derivative thereof, of which the most bathochromic solution absorption peak in the visible spectrum is at from 575 to 615 nm, preferably at from 585 to 605 nm (as compared with around 630 nm for usual 1,4-diamino-anthraquinone dyes or 1,9-annellated derivatives thereof) is used in combination with α copper phthalocyanine or ε copper phthalocyanine. Also claimed are colour filters comprising such 1,4-diamino-anthraquinone dyes or 1,9-annellated derivatives thereof, as well as a novel compound of Formula (II), wherein R | 09-09-2010 |
20120100395 | INDICATOR SYSTEM FOR MONITORING A STERILIZATION PROCESS - The present invention relates to a device for monitoring integral value of time, temperature comprising at least one layer of polymer comprising a latent pigment capable of undergoing at least one colour change, and an organic acid; or comprising one layer of polymer comprising a latent pigment capable of undergoing at least one colour change, and one layer of polymer comprising an organic acid, wherein said latent pigment is converted to its pigmentary form which causes said colour change. The device can be used for monitoring sterilization of medical and kitchen supplies, canned foods and doneness of microwave foods. | 04-26-2012 |
Véronique Hebmann, Saint Bauzille De Montmel FR
Patent application number | Description | Published |
---|---|---|
20110064793 | INHIBITORS OF HIV REPLICATION AND METHOD OF TREATMENT OF HIV INFECTIONS - The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections. | 03-17-2011 |
Véronique Hebmann, Saint Bauzille De Montmel FR
Patent application number | Description | Published |
---|---|---|
20110064793 | INHIBITORS OF HIV REPLICATION AND METHOD OF TREATMENT OF HIV INFECTIONS - The invention is drawn to a novel class of drugs directed against HIV, comprising a peptide or analog comprising a decapeptide, said decapeptide containing (from N-terminus to the C-terminus) a basic amino acid in position 1, an acidic amino acid in positions 2 and 5, and a tryptophan in positions 4, 7, and 8, and to a method of treatment of HIV infections, in particular multidrug-resistant HIV infections. | 03-17-2011 |
Véronique Laretta-Garde, L'Isle D'Adam FR
Patent application number | Description | Published |
---|---|---|
20100330157 | BIOMATERIAL FOR THE CONTROLLED DELIVERY OF INGREDIENTS - The disclosure relates to a biomaterial that comprises an aqueous phase, polymer network, a second polymer included in said disclosure invention more particularly relates to a biomaterial including an aqueous phase and a first polymer network made of a first proteic or saccharidic polymer or a mixture of first proteic and saccharidic polymers, wherein the first polymer network and the aqueous phase define a first gel (A), the biomaterial including: a second proteic or saccharidic polymer or a mixture of the second proteic and saccharidic polymers, either in solution in the aqueous phase of the gel (A) or in the form of a gel (B), and a first enzyme for degrading said second polymer or second polymer network. The disclosure also relates to a method for making biomaterials, and to the uses of the biomaterial particularly for releasing active substances, and to a device for the controlled release of active substances that include the biomaterial. The disclosure can particularly be used in the field of cosmetics and pharmaceuticals. | 12-30-2010 |
Véronique Laretta-Garde, L'Isle D'Adam FR
Patent application number | Description | Published |
---|---|---|
20100330157 | BIOMATERIAL FOR THE CONTROLLED DELIVERY OF INGREDIENTS - The disclosure relates to a biomaterial that comprises an aqueous phase, polymer network, a second polymer included in said disclosure invention more particularly relates to a biomaterial including an aqueous phase and a first polymer network made of a first proteic or saccharidic polymer or a mixture of first proteic and saccharidic polymers, wherein the first polymer network and the aqueous phase define a first gel (A), the biomaterial including: a second proteic or saccharidic polymer or a mixture of the second proteic and saccharidic polymers, either in solution in the aqueous phase of the gel (A) or in the form of a gel (B), and a first enzyme for degrading said second polymer or second polymer network. The disclosure also relates to a method for making biomaterials, and to the uses of the biomaterial particularly for releasing active substances, and to a device for the controlled release of active substances that include the biomaterial. The disclosure can particularly be used in the field of cosmetics and pharmaceuticals. | 12-30-2010 |
Véronique Le Sant, Le Mesnil Saint Denis FR
Patent application number | Description | Published |
---|---|---|
20130215927 | DEVICE FOR MEASURING A HEAT FLUX - The invention relates to a device for measuring a heat flux, comprising a thermopile formed of a plurality of thermojunctions of distributed type. The device is formed of a first and a second ceramic substrate (Ce | 08-22-2013 |
Véronique Maquet, Berloz BE
Patent application number | Description | Published |
---|---|---|
20100003292 | FINE-GRANULOMETRY FUNGAL EXTRACT CHITINE-GLUCANE - The present invention relates to a chitin-glucan copolymer in the form of micrometric particles. | 01-07-2010 |
20130156836 | Chitosan Bornet - The invention relates to a chitosan as a micronized powder, to its use for controlling certain yeasts, such as | 06-20-2013 |
Véronique Migonney, Eaubonne FR
Patent application number | Description | Published |
---|---|---|
20090318622 | Method for Grafting Bioactive Polymers on Prosthetic Materials - The invention concerns methods for grafting bioactive polymers on a prosthetic material, the materials obtainable by said method and applications thereof. More specifically, the invention concerns a method for directly grafting polymers on the surface of prosthetic materials. | 12-24-2009 |
Véronique Migonney, Eaubonne FR
Patent application number | Description | Published |
---|---|---|
20090318622 | Method for Grafting Bioactive Polymers on Prosthetic Materials - The invention concerns methods for grafting bioactive polymers on a prosthetic material, the materials obtainable by said method and applications thereof. More specifically, the invention concerns a method for directly grafting polymers on the surface of prosthetic materials. | 12-24-2009 |
Véronique Monjardet, Paris FR
Patent application number | Description | Published |
---|---|---|
20100015056 | Uranium-chelating peptides and uses thereof - The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence. | 01-21-2010 |
20110093964 | URANIUM-CHELATING PEPTIDES AND USES THEREOF - The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence. | 04-21-2011 |
Véronique Monjardet, Paris FR
Patent application number | Description | Published |
---|---|---|
20100015056 | Uranium-chelating peptides and uses thereof - The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence. | 01-21-2010 |
20110093964 | URANIUM-CHELATING PEPTIDES AND USES THEREOF - The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence. | 04-21-2011 |
Véronique Morisson-Iveson, Amersham GB
Patent application number | Description | Published |
---|---|---|
20120034165 | IMAGING THE CENTRAL NERVOUS SYSTEM WITH PURINERGIC P2X7 RECEPTOR BINDING AGENTS - The present invention provides novel compounds which may be used as in vivo imaging agents. The compounds of the invention are useful in a method to image the expression of P2X7 receptors in a subject, as a means to facilitate the diagnosis of a range of disease states. | 02-09-2012 |
Véronique Nery, Boussens CH
Patent application number | Description | Published |
---|---|---|
20130126438 | INSTALLATION AND PROCESS FOR RECYCLING WIPING SOLUTION OF ONE OR MORE INTAGLIO PRINTING PRESSES - There is described an installation ( | 05-23-2013 |
Véronique Orian-Rousseau, Rittershofen FR
Patent application number | Description | Published |
---|---|---|
20100305026 | CD44V6 peptides as inhibitors of bacterial infections - The present invention relates to the use of peptide compounds for the prevention and/or treatment of a bacterial infection. | 12-02-2010 |
20120115794 | USE OF CD44V6 IN THE TREATMENT OF OPHTHALMIC DISEASES - The present invention relates to the use of peptide compounds for the prevention and/or treatment of ophthalmic diseases. In particular, the present invention relates to a peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 (KEQWFGNRWHEGYR) or of SEQ ID NO: 1 (KEKWFENEWQGKNP), or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatmend of an ophthalmic disease in an individual. While SEQ ID NO: 2 is a part of the human CD44v6, SEQ ID NO: 1 is a part of the rat CD44v6. | 05-10-2012 |
Véronique Orian-Rousseau, Rittershofen FR
Patent application number | Description | Published |
---|---|---|
20100305026 | CD44V6 peptides as inhibitors of bacterial infections - The present invention relates to the use of peptide compounds for the prevention and/or treatment of a bacterial infection. | 12-02-2010 |
20130072423 | CD44V6 PEPTIDES AS INHIBITORS OF BACTERIAL INFECTIONS - The present invention relates to the use of peptide compounds for the prevention and/or treatment of a bacterial infection. | 03-21-2013 |
20130109632 | USE OF VEGFR-2 IN THE TREATMENT OF OPHTHALMIC DISEASES | 05-02-2013 |
Véronique Pauchon, Venejan FR
Patent application number | Description | Published |
---|---|---|
20130061780 | METHOD FOR PREPARING A COMPOSITE MATERIAL FROM WASTE AND RESULTING MATERIAL - A method for preparing a composite material from a waste appearing as sludge is provided. The method comprises a step consisting in putting said waste appearing as sludge in contact with a dry cement mixture. Also provided are the thereby obtained composite material and the use of such a method for treating and/or inertizing wastes and notably industrial and/or radioactive wastes. | 03-14-2013 |
Véronique Pêtre, Ceroux-Mousty BE
Patent application number | Description | Published |
---|---|---|
20130089639 | Low Glycaemic Index Baked Product Comprising High Levels of Fibre, Proteins and Inclusions - The present invention is directed to a bread product which is particularly adapted for breakfast, and which is characterized by high satietogenic and nutritional properties, and its convenience of use. Said bread product comprises 8-25 wt % of proteins, more than 6 wt % of fibres and 18-35 wt % of inclusions having an average size of at least 2 mm. | 04-11-2013 |
Véronique Poulain, Mons BE
Patent application number | Description | Published |
---|---|---|
20110027587 | Stable Thermistor - A thermistor based on a composition having the general formula (I): Re | 02-03-2011 |
Véronique Poulain, Mons BE
Patent application number | Description | Published |
---|---|---|
20110027587 | Stable Thermistor - A thermistor based on a composition having the general formula (I): Re | 02-03-2011 |
Véronique Preat, Kraainem BE
Patent application number | Description | Published |
---|---|---|
20110112115 | POLYMERIC MICROEMULSIONS - The invention provides novel self-emulsifying diblock copolymers and novel self-emulsifying compositions comprising an active ingredient and a diblock copolymer characterized in that the diblock copolymer is liquid at a temperature below 50° C. and the composition is non-aqueous and liquid at a temperature below 50° C. | 05-12-2011 |
Véronique Preat, Kraainem BE
Patent application number | Description | Published |
---|---|---|
20110112115 | POLYMERIC MICROEMULSIONS - The invention provides novel self-emulsifying diblock copolymers and novel self-emulsifying compositions comprising an active ingredient and a diblock copolymer characterized in that the diblock copolymer is liquid at a temperature below 50° C. and the composition is non-aqueous and liquid at a temperature below 50° C. | 05-12-2011 |
20150086504 | POLYMERIC MICROEMULSIONS - The invention provides novel self-emulsifying diblock copolymers and novel self-emulsifying compositions comprising an active ingredient and a diblock copolymer characterized in that the diblock copolymer is liquid at a temperature below 50° C. and the composition is non-aqueous and liquid at a temperature below 50° C. | 03-26-2015 |
Véronique Rebuffel, Corenc FR
Patent application number | Description | Published |
---|---|---|
20110204245 | PHOTONIC RADIATION DETECTION DEVICE, AND METHODS FOR DIMENSIONING AND OPERATING SUCH DEVICE - A photonic radiation detection device includes a collimator, a detector, means for localization in the detection plane defining on the one hand the partitioning of the detection plane in physical or virtual pixels of transversal dimensions smaller than those of the collimator channels, and associating on the other hand one of said pixels to each photon interaction. The detection device has at least in one previously selected acquisition configuration, a degree of pixelation in the detection plane greater than 1 and a collimator-detector distance (c) greater than one tenth of the septal height (h) of the collimator. A method for dimensioning such a device includes, for at least one given spatial frequency, calculating and comparing merit indicator values for different acquisition configurations of a structural model of the detection device. | 08-25-2011 |
20110260072 | Gamma-Camera Utilizing the Interaction Depth in a Detector - A method for underwater packaging of radioactive materials includes creating a vacuum in a cavity of a cleaning device to automatically cause a portion of the cleaning device to move upward to actuate the cleaning device from an open position to a closed position; mounting the cleaning device inside a safe containment area of a transportation and/or storage device; placing the transportation and/or storage device in a pool after filling the safe containment area with water; loading a radioactive material into the safe containment area; closing the transportation and/or storage device using at least one cover; extracting the transportation and/or storage device from the pool; draining the water inside the safe containment area; and creating a pressure differential in the safe containment area to dry the safe containment area, wherein the pressure differential causes the cleaning device to automatically actuate from the closed position to the open position. | 10-27-2011 |
Véronique Rosilio, Paris FR
Patent application number | Description | Published |
---|---|---|
20090130214 | Gemcitabine derivatives nanoparticles - The invention concerns a 2′,2′-difluoro-2′-deoxycytidine derivative of general formula (I), wherein: R | 05-21-2009 |
20100160249 | NANOPARTICLE DERIVATIVES OF GEMCITABINE - The use of squalenic acid or a derivative thereof in formulating at least one polar active principle with a molecular weight of 100 Da or more, in the form of nanoparticles, and pharmaceutical compositions thereof. | 06-24-2010 |
Véronique Rosilio, Paris FR
Patent application number | Description | Published |
---|---|---|
20100160249 | NANOPARTICLE DERIVATIVES OF GEMCITABINE - The use of squalenic acid or a derivative thereof in formulating at least one polar active principle with a molecular weight of 100 Da or more, in the form of nanoparticles, and pharmaceutical compositions thereof. | 06-24-2010 |
Véronique Rossow, Arcachon FR
Patent application number | Description | Published |
---|---|---|
20100080833 | STABLE, CONCENTRATED AND DILUTE, OIL-IN-WATER EMULSIONS, THEIR PROCESSES OF PREPARATION, AND FORMULATION PROCESS EMPLOYING THESE EMULSIONS - A stable oil-in-water emulsion, a process for the preparing such emulsion, and a formulation process employing the emulsion. The stable oil-in-water emulsion is obtained from an air-in-water preemulsion to which a simple or complex fatty substance is added by moderate mixing, preferably without exerting a shear force. The air-in-water preemulsion includes a surfactant, preferably a nonionic surfactant, a co surfactant chosen from hydrophilic compounds, preferably having at least one hydroxyl group, which are chosen in particular from the family of the polyols, and an aqueous phase. The ratios of these three components of the preemulsion are chosen within the region of ordered liquid crystal structure of the phase diagram of these three components and/or in ratios chosen so that the structure of the mixture of these three components, observed under a microscope in polarized light, exhibits birefringence characteristics. | 04-01-2010 |
Véronique Zennou, Paris FR
Patent application number | Description | Published |
---|---|---|
20110250650 | LENTIVIRAL VECTORS FOR THE PREPARATION OF IMMUNOTHERAPEUTICAL COMPOSITIONS - The invention relates to an immunogenic composition comprising a recombinant vector characterized in that it comprises a polynucleotide comprising the cis-acting central initiation region (cPPT) and the cis-acting termination region (CTS), these regions being of retroviral or retroviral-like origin, said vector comprising in addition a defined nucleotide sequence (transgene or sequence of interest) and regulatory signals of retrotranscription, expression and encapsidation of retroviral or retroviral-like origin, wherein the composition is capable of inducing or of stimulating a cell-mediated response for instance a CTL (Cytotoxic T Lymphocytes) response or a CD4 response, against one or several epitopes encoded by the transgene sequence present in the vector. | 10-13-2011 |
20120095083 | USE OF TRIPLEX STRUCTURE DNA IN TRANSFERRING NUCLEOTIDE SEQUENCES - A method to induce an immune response in a host in need thereof, comprises administering to the host, recombinant lentiviral vector particles comprising: | 04-19-2012 |
20120252113 | USE OF TRIPLEX STRUCTURE DNA IN TRANSFERRING NUCLEOTIDE SEQUENCES - The invention concerns a recombinant vector characterized in that it comprises a polynucleotide comprising a central initiation cis-active region (cPPT) and a termination cis-active region (CTS), the regions being of retroviral or retroviral-like origin, and the vector further comprising a predetermined nucleotide sequence (transgene or nucleotide sequence of interest) and retrotranscription regulating, expressing, and packaging signals of retroviral or retroviral-like origin. | 10-04-2012 |
20120252114 | USE OF TRIPLEX STRUCTURE DNA IN TRANSFERRING NUCLEOTIDE SEQUENCES - The invention concerns a recombinant vector characterized in that it comprises a polynucleotide comprising a central initiation cis-active region (cPPT) and a termination cis-active region (CTS), the regions being of retroviral or retroviral-like origin, and the vector further comprising a predetermined nucleotide sequence (transgene or nucleotide sequence of interest) and retrotranscription regulating, expressing, and packaging signals of retroviral or retroviral-like origin. | 10-04-2012 |